36.29
0.79 (2.23%)
| Previous Close | 35.50 |
| Open | 35.42 |
| Volume | 989,717 |
| Avg. Volume (3M) | 1,468,039 |
| Market Cap | 2,871,988,992 |
| Price / Book | 5.06 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -3.75 |
| Current Ratio (MRQ) | 26.48 |
| Operating Cash Flow (TTM) | -192.66 M |
| Levered Free Cash Flow (TTM) | -122.17 M |
| Return on Assets (TTM) | -35.87% |
| Return on Equity (TTM) | -56.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Mineralys Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 103.83% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalys Pacific, Llc | 30 Sep 2025 | 8,903,838 |
| Samsara Biocapital, Llc | 30 Sep 2025 | 6,263,151 |
| Laurion Capital Management Lp | 30 Sep 2025 | 1,720,445 |
| Farallon Capital Management Llc | 30 Sep 2025 | 1,673,053 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (HC Wainwright & Co., 54.31%) | Buy |
| Median | 55.00 (51.56%) | |
| Low | 52.00 (Stifel, 43.29%) | Buy |
| Average | 54.33 (49.71%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 43.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 19 Dec 2025 | 52.00 (43.29%) | Buy | 36.83 |
| HC Wainwright & Co. | 12 Nov 2025 | 56.00 (54.31%) | Buy | 47.33 |
| 30 Oct 2025 | 52.00 (43.29%) | Buy | 41.12 | |
| Wells Fargo | 11 Nov 2025 | 55.00 (51.56%) | Buy | 47.11 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |